- Trulicity (dulaglutide) has been approved in the EU for treatment of patients with type 2 diabetes.
- Trulicity is part of a class of drugs known as GLP-receptor agonists. Other drugs in this class include Victoza (liraglutide).
- Trulicity was approved by the FDA on September 18.
The whole point of a drug like Trulicity is providing a more convenient treatment option for patients with type 2 diabetes, a chronic disease that often requires lifelong therapy. Because of its weekly dosing schedule, patients are likely to be more compliant. In addition, its user friendly features, including a single-dose pen, no mixing or handling needles and no measuring, bode well for patient acceptance and product uptake.